Video Article

Lipid Vesicle-mediated Affinity Chromatography using Magnetic Activated Cell Sorting (LIMACS): a Novel Method to Analyze Protein-lipid Interaction

Erhard Bieberich

Institute of Molecular Medicine and Genetics, Georgia Health Sciences University

Correspondence to: Erhard Bieberich at ebieberich@mcg.edu

URL: <http://www.jove.com/details.php?id=2657>

DOI: 10.3791/2657

Citation: Bieberich E. (2011). Lipid Vesicle-mediated Affinity Chromatography using Magnetic Activated Cell Sorting (LIMACS): a Novel Method to Analyze Protein-lipid Interaction. JoVE. 50. <http://www.jove.com/details.php?id=2657>, doi: 10.3791/2657

Abstract

The analysis of lipid protein interaction is difficult because lipids are embedded in cell membranes and therefore, inaccessible to most purification procedures. As an alternative, lipids can be coated on flat surfaces as used for lipid ELISA and Plasmon resonance spectroscopy. However, surface coating lipids do not form microdomain structures, which may be important for the lipid binding properties. Further, these methods do not allow for the purification of larger amounts of proteins binding to their target lipids.

To overcome these limitations of testing lipid protein interaction and to purify lipid binding proteins we developed a novel method termed lipid vesicle-mediated affinity chromatography using magnetic-activated cell sorting (LIMACS). In this method, lipid vesicles are prepared with the target lipid and phosphatidylserine as the anchor lipid for Annexin V MACS. Phosphatidylserine is a ubiquitous cell membrane phospholipid that shows high affinity to the protein Annexin V. Using magnetic beads conjugated to Annexin V the phosphatidylserine-containing lipid vesicles will bind to the magnetic beads. When the lipid vesicles are incubated with a cell lysate the protein binding to the target lipid will also be bound to the beads and can be co-purified using MACS. This method can also be used to test if recombinant proteins reconstitute a protein complex binding to the target lipid.

We have used this method to show the interaction of atypical PKC (aPKC) with the sphingolipid ceramide and to co-purify prostate apoptosis response 4 (PAR-4), a protein binding to ceramide-associated aPKC. We have also used this method for the reconstitution of a ceramide-associated complex of recombinant aPKC with the cell polarity-related proteins Par6 and Cdc42. Since lipid vesicles can be prepared with a variety of sphingo- or phospholipids, LIMACS offers a versatile test for lipid-protein interaction in a lipid environment that resembles closely that of the cell membrane. Additional lipid protein complexes can be identified using proteomics analysis of lipid binding protein co-purified with the lipid vesicles.

Protocol

1. Introduction

The lipid vesicle-mediated affinity chromatography using magnetic-activated cell sorting (LIMACS) technique was developed in our laboratory to isolate ceramide-associated protein complexes¹⁻³. Originally, the lipid vesicles were made of ceramide and phosphatidylserine, which allowed for MACS using magnetic particle-conjugated Annexin V (highly affine to phosphatidylserine) to isolate the vesicles and their associated proteins. We have used the LIMACS technique for the *in vitro* reconstitution of a ceramide-associated polarity complex and the isolation of ceramide-binding proteins from cell lysates³. LIMACS can be modified using other interaction partners for the isolation of the vesicles (e.g., glycolipid-specific lectins or lipid antibodies).

2. Experimental Procedures

Preparation of Lipid Vesicles and aPKC Binding Assays

1. Lipid vesicles are obtained from dried mixtures of equimolar amounts of phosphatidylserine (105 µg) and C16-ceramide (85 µg) following modified procedures for large liposome preparation^{1,4-7}.
2. The lipid mixtures are then resuspended and sonicated for 1 h in 100 µl of vesicle buffer consisting of 50 mM Tris/HCl (pH 7.5) and 150 mM NaCl.
3. After adding 300 µl of vesicle buffer supplemented with 0.1 mM MnCl₂, the samples are centrifuged at 12,000 µg for 20 min at 4 °C.
4. The pellet (large lipid vesicles) is resuspended in 100 µl of vesicle buffer and incubated with 1 nmol of Vybrant CM-dil for 1 h at 37 °C to visualize the vesicle fraction after MACS separation. Vybrant CM-dil is a red fluorescent dye specifically incorporating into lipid membranes.
5. A detergent-free cell lysate is prepared by sonication/homogenization of cells in 300 µl of hypotonic buffer (10 mM Tris/HCl (pH 7.0) with protease and phosphatase inhibitors) followed by removal of membranous debris by centrifugation. A centrifugation step at 100,000xg for 1 h should be added to avoid contamination of the cell lysate with endogenous membranes containing phosphatidylserine.
6. The cleared lysate is added to the lipid vesicle suspension, and the mixture is incubated for 2 h at 4 °C.
7. The reaction mixture is supplemented with 20 µl of 20x Annexin V binding buffer and 50 µl of a solution containing magnetic beads conjugated to Annexin V followed by incubation for 1 h at 4 °C.
8. MACS is performed according to the manufacturer's (Miltenyi Biotec, Inc.) protocol. The presence and quantity of lipid vesicles is determined by monitoring the Vybrant CM-dil fluorescence in the flow-through and elution fractions using a microplate fluorescence reader.
9. The linear correlation between the amount of vesicular lipid and fluorescence intensity of vesicle-bound Vybrant CM-dil is verified by quantitative high-performance thin-layer chromatography (HPTLC) of the lipid mixture applied to Annexin V-based MACS.

10. The specificity of the binding reaction of aPKC or other proteins to the ceramide/phosphatidylserine vesicles is verified by an antibody competition assay using 1 μ g of anti-PKC ζ rabbit polyclonal antibody to incubate the cell lysate for 1 h at 4 $^{\circ}$ C prior to incubation with the lipid vesicles.
11. The protein binding to ceramide/phosphatidylserine vesicles in the MACS eluate is analyzed by SDS-PAGE and immunoblotting.

In vitro lipid-protein polarity complex

1. The *in vitro* reconstitution of a lipid-protein polarity complex is performed following the LIMACS procedure as described in the previous section. In brief, phosphatidylserine (420 μ g) and C16-ceramide (107 μ g) is dried from organic solvent.
2. The dried lipids are resuspended under sonication in 500 μ l of vesicle buffer (50 mM Tris/HCl, pH 7.5; 150 mM NaCl).
3. Five μ l of 10 mM MnCl₂, 1 μ l of Vybrant CM-dil, and 500 ng of PKC ζ (human recombinant) is added and the reaction mixture incubated under gentle agitation for 60 min at 4 $^{\circ}$ C.
4. Vybrant CM-dil stained phosphatidylserine/ceramide vesicles are recovered by centrifugation at 12,000xg for 60 min at 4 $^{\circ}$ C.
5. The pellet (pink) is resuspended in 100 μ l Tris buffer and supplemented with γ S-GTP (100 μ M), GDP (1 mM), GST-Par6 (100 ng), or GST-Cdc42 (500 ng) and further incubated for 3 h at 4 $^{\circ}$ C (*any other combination of recombinant proteins of interest can be used here*).
6. Annexin V-buffer (5 μ l of a 20x stock solution) and Annexin V-conjugated magnetic beads (50 μ l) are added and the reaction mixture incubated under gentle agitation for another 30 min at 4 $^{\circ}$ C.
7. Annexin V-MACS is performed following the supplier's protocol as described previously.
8. The elution fraction (1 ml) is supplemented with 10 μ g of pure ovalbumin as precipitation aid. The protein is concentrated by Wessel-Flugge precipitation and analyzed by SDS-PAGE/immunoblotting as previously described ⁸.
9. The amount of eluted lipid vesicles is quantified by the detection of Vybrant CM-dil (pink) in the organic (chloroform/methanol) phase of the Wessel Flugge precipitation reaction. The amount of protein analyzed is normalized on equal amounts of lipid vesicles.

3. Results

LIMACS purification of PKC ζ -EGFP and the ceramide binding domain C20 ζ -EGFP

A detergent-free lysate of MDCK cells expressing full length PKC ζ C-terminally linked to green fluorescent protein (FL ζ -EGFP) or a ceramide binding domain in the C-terminus of PKC ζ (C20 ζ -EGFP) was incubated with phosphatidylserine/ceramide vesicles as described in Experimental Procedures. After elution of the MACS column, protein was analyzed using immunoblotting and antibodies against PKC ζ and EGFP for detection of the eluted protein ².

Figure 1. LIMACS of EGFP-labeled PKC ζ and its C-terminal fragment C20 ζ using phosphatidylserine/ceramide vesicles.

Detergent-free lysates of MDCK cells expressing EGFP (as a non-binding control), full length PKC ζ -EGFP, or the ceramide binding, C-terminal fragment C20 ζ -EGFP were incubated with phosphatidylserine/ceramide vesicles as described in the Experimental Procedures section. After using LIMACS, protein was eluted with SDS sample buffer and analyzed by SDS-PAGE and immunoblotting. The left panel shows that EGFP did not bind to the vesicles retained with the Annexin V-linked magnetic beads. The middle and right panel shows that full length PKC ζ -EGFP and C20 ζ -EGFP were retained due to binding to ceramide.

Discussion

To test the specific interaction between a lipid and its binding protein is hampered by embedding of lipids in the cell membrane. The cell membrane consists of a mixture of several lipids and proteins and it is organized in lipid microdomains or rafts. Therefore, the co-purification of microdomains and proteins cannot clearly distinguish if a protein directly binds to a lipid or is only enriched in a microdomain structure. Other methods using defined lipids coated on surfaces such as lipid ELISAs or Plasmon resonance spectroscopy can detect the interaction of a specific lipid with its binding protein. However, to determine this interaction in a physiologically relevant membrane environment, the surface (e.g., for Plasmon resonance spectroscopy) has to be coated with lipid vesicles or liposomes.

We developed a novel lipid vesicle binding assay as an alternative to these previous methods. The novelty comes from incorporating an anchor lipid (phosphatidylserine) into the vesicles, which allows for the isolation of lipid vesicles with Annexin V-conjugated magnetic beads. Therefore, we termed this assay lipid vesicle-mediated affinity chromatography using magnetic activated cell sorting (LIMACS). LIMACS can be performed for endogenous proteins, proteins expressed in cells, or recombinant proteins reconstituted in a lipid protein complex ¹⁻³.

The protein bound to the lipid vesicles can then be recovered by simply taking the MACS column from the magnetic stand and eluting it with an appropriate buffer. This can be an enzyme compatible buffer to measure enzyme activity in the eluate or SDS sample buffer to perform protein

analysis using SDS-PAGE and immunoblotting. If using SDS sample buffer the MACS column does not have to be removed from the magnetic stand, which allows for retention of the magnetic beads on the stand.

There are precautions to be taken when using LIMACS. Evidently, LIMACS cannot be used with a detergent lysate because this will destroy the lipid vesicles. Also, it has to be tested if the binding protein of the target lipid also binds to phosphatidylserine because this lipid is used as an anchor for binding of the vesicles to Annexin V-conjugated magnetic beads. In some cases, phosphatidylserine may impair binding to the target protein. Therefore, negative controls and controls with various amounts of phosphatidylserine have to be included into the assay. These controls can be easily performed by using lipid vesicles containing only phosphatidylserine or a mixture of phosphatidylserine with non-binding lipids. Including negative controls is also required for cell lysates that contain a significant amount of endogenous phosphatidylserine. To avoid contamination with endogenous lipid membranes or vesicles it is recommended to clear the cell lysate by including an ultracentrifugation step at 100,000xg for 1 h. It is evident that lipid binding proteins in the supernatant can only be cytosolic, which is a limitation of the LIMACS procedure. There is the possibility to extend LIMACS to other anchor lipids such as GM1 and cholera toxin B subunit conjugated with magnetic beads.

We are currently exploring the use of lipid-specific antibodies for LIMACS, which would make the use of anchor lipids for preparation of the vesicles unnecessary. One of the beneficial aspects of LIMACS is the isolation of the lipid protein complex which allows for a variety of protein analytical methods that are not implementable. For example, we have used LIMACS to isolate a reconstituted polarity protein complex of Par6/Cdc42 associated with ceramide-bound aPKC. Therefore, LIMACS is a powerful novel method for the analysis and isolation of lipid-associated protein complexes.

Disclosures

No conflicts of interest declared.

Acknowledgements

This work was supported by the NIH grants R01NS046835 and R01AG034389, and the March of Dimes grant 6FY08-322. A special thank you is devoted to Mrs. Eleanor Brown (Miltenyi Biotec, Auburn, CA) who helped tremendously with her insight into the MACS technology. Miltenyi has generously provided the material used for the demonstration of the experiments at no cost. I am also grateful to Dr. Guanghu Wang (Medical College of Georgia/Georgia Health Sciences University, Augusta, GA) who generated the PKC ζ expressing cell lines. Support by the Institute of Molecular Medicine at the Medical College of Georgia/Georgia Health Sciences University (under directorship of Dr. Lin Mei) is also acknowledged.

References

1. Wang, G. *et al.* Direct binding to ceramide activates protein kinase C ζ before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. *J Biol Chem* **280**, 26415-26424 (2005).
2. Wang, G., Krishnamurthy, K., Umapathy, N. S., Verin, A. D. & Bieberich, E. The carboxyl-terminal domain of atypical protein kinase C ζ binds to ceramide and regulates junction formation in epithelial cells. *J Biol Chem* **284**, 14469-14475,
3. Wang, G., Krishnamurthy, K., Chiang, Y. W., Dasgupta, S. & Bieberich, E. Regulation of neural progenitor cell motility by ceramide and potential implications for mouse brain development. *J Neurochem* **106**, 718-733 (2008).
4. Chalfant, C. E. *et al.* De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. *J Biol Chem* **277**, 12587-12595 (2002).
5. Simon, C. G., Jr., Holloway, P. W. & Gear, A. R. Exchange of C(16)-ceramide between phospholipid vesicles. *Biochemistry* **38**, 14676-14682 (1999).
6. Goni, F. M., Contreras, F. X., Montes, L. R., Sot, J. & Alonso, A. Biophysics (and sociology) of ceramides. *Biochem Soc Symp*, 177-188 (2005).
7. Kumagai, K. *et al.* CERT mediates intermembrane transfer of various molecular species of ceramides. *J Biol Chem* **280**, 6488-6495 (2005).
8. Wessel, D. & Flugge, U. I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. *Anal Biochem* **138**, 141-143, doi:0003-2697(84)90782-6 [pii] (1984).